CLINICAL TRIALS PROFILE FOR BIFEPRUNOX

Clinical Trials for Bifeprunox

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00134459 ↗	Study Evaluating Bifeprunox in Bipolar Depression	Completed	Solvay Pharmaceuticals	Phase 3	The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
NCT00134459 ↗	Study Evaluating Bifeprunox in Bipolar Depression	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
NCT00139906 ↗	Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia	Completed	H. Lundbeck A/S	Phase 2	This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
NCT00139906 ↗	Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2	This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
NCT00139906 ↗	Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia	Completed	Solvay Pharmaceuticals	Phase 2	This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
NCT00139919 ↗	Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder	Completed	H. Lundbeck A/S	Phase 2	This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.
NCT00139919 ↗	Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2	This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.

Clinical Trial Conditions for Bifeprunox

Condition Name

Condition Name
Intervention	Trials
Schizophrenia	14
Schizoaffective Disorder	3
Bipolar Disorder	2
Bipolar I Disorder	1

Condition MeSH

Condition MeSH
Intervention	Trials
Schizophrenia	15
Psychotic Disorders	5
Depression	2
Bipolar Disorder	2

Clinical Trial Locations for Bifeprunox

Trials by Country

Trials by Country
Location	Trials
United States	208
Canada	8
Estonia	3
Czech Republic	3
Argentina	2

Trials by US State

Trials by US State
Location	Trials
California	11
Georgia	10
Texas	9
Pennsylvania	9
Oklahoma	9

Clinical Trial Progress for Bifeprunox

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	15
Phase 2	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	13
Terminated	7

Clinical Trial Sponsors for Bifeprunox

Sponsor Name

Sponsor Name
Sponsor	Trials
Solvay Pharmaceuticals	14
Wyeth is now a wholly owned subsidiary of Pfizer	13
H. Lundbeck A/S	9

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	36